498-95-3Relevant articles and documents
Catalytic Asymmetric Synthesis of Unprotected β2-Amino Acids
Zhu, Chendan,Mandrelli, Francesca,Zhou, Hui,Maji, Rajat,List, Benjamin
, p. 3312 - 3317 (2021/04/07)
We report here a scalable, catalytic one-pot approach to enantiopure and unmodified β2-amino acids. A newly developed confined imidodiphosphorimidate (IDPi) catalyzes a broadly applicable reaction of diverse bis-silyl ketene acetals with a silylated aminomethyl ether, followed by hydrolytic workup, to give free β2-amino acids in high yields, purity, and enantioselectivity. Importantly, both aromatic and aliphatic β2-amino acids can be obtained using this method. Mechanistic studies are consistent with the aminomethylation to proceed via silylium-based asymmetric counteranion-directed catalysis (Si-ACDC) and a transition state to explain the enantioselectivity is suggested on the basis of density functional theory calculation.
AN ECO-FRIENDLY PROCESS FOR HYDROGENATION OR/AND HYDRODEOXYGENATION OF ORGANIC COMPOUND USING HYDROUS RUTHENIUM OXIDE CATALYST
-
Page/Page column 15; 22, (2017/08/01)
The invention discloses aneco-friendly process for hydrogenation (alkenealkene, carbonyl compound and aromatic) and hydrodeoxygenation (methoxy phenols) of organic compound using hydrous ruthenium oxide (HRO) and its supported form as a recyclable heterogeneous catalyst in aqueous medium with good yield of desired compounds (70-100%) under mild reaction conditions. The invention also discloses hydrogenation of organic compound such as alkene, carbonyl compound and substituted aromatic and also for the processes that involve hydrodeoxygenation, for example, lignin derived aromatic (methoxy phenols).
Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)
Futatsugi, Kentaro,Kung, Daniel W.,Orr, Suvi T. M.,Cabral, Shawn,Hepworth, David,Aspnes, Gary,Bader, Scott,Bian, Jianwei,Boehm, Markus,Carpino, Philip A.,Coffey, Steven B.,Dowling, Matthew S.,Herr, Michael,Jiao, Wenhua,Lavergne, Sophie Y.,Li, Qifang,Clark, Ronald W.,Erion, Derek M.,Kou, Kou,Lee, Kyuha,Pabst, Brandon A.,Perez, Sylvie M.,Purkal, Julie,Jorgensen, Csilla C.,Goosen, Theunis C.,Gosset, James R.,Niosi, Mark,Pettersen, John C.,Pfefferkorn, Jeffrey A.,Ahn, Kay,Goodwin, Bryan
supporting information, p. 7173 - 7185 (2015/10/05)
The medicinal chemistry and preclinical biology of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2) is described. A screening hit 1 with low lipophilic efficiency (LipE) was optimized through two key structural modifications: (1) identification of the pyrrolidine amide group for a significant LipE improvement, and (2) insertion of a sp3-hybridized carbon center in the core of the molecule for simultaneous improvement of N-glucuronidation metabolic liability and off-target pharmacology. The preclinical candidate 9 (PF-06424439) demonstrated excellent ADMET properties and decreased circulating and hepatic lipids when orally administered to dyslipidemic rodent models.